

Supplementary Materials

Instrument AVC500
Group MGM
0448 Georgia Clarke 20/2/15

NMR@CHEM.OX




Figure S1. ^1H NMR data for compound 2.

Instrument AVC500
Group MGM
0448 Georgia Clarke 20/2/15

NMR@CHEM.OX




Figure S2. ^{13}C NMR data for compound 2.

Instrument AVC500
Group MGM
1013 Georgia Clarke 20/4/15




Figure S3. ^1H NMR data for compound 4.

Instrument AVC500
Group MGM
1013 Georgia Clarke 20/4/15




Figure S4. ^{13}C NMR data for compound 4.




Figure S5. DEPT-135-NMR data for compound 4.




Figure S6. COSY data for compound 4.




Figure S7. HSQC data for compound 4.






Figure S8. HMBC data for compound 4.

Table S1. Antibacterial activity of Compound 4 (n/a = no activity).

Activity	Zone diameter/mm (average of triplicate assay)	Relative Potency (Ceph C)/ nmol·well ⁻¹
<i>E. coli</i>	15	1.15
<i>S. aureus</i>	n/a	n/a

*1: Cephalosporin Calibration for E. coli.**2: Cephalosporin Calibration for S. aureus***Figure S9.** Calibration curves for antibacterial activity of Cephalosporin C against *S. aureus* and *E. coli*.